{"log_id": 2596123935005688800, "direction": 0, "words_result_num": 40, "words_result": [{"probability": {"variance": 0.003001, "average": 0.990227, "min": 0.639605}, "location": {"width": 855, "top": 159, "height": 41, "left": 201}, "words": "氨蝶呤单独使用之间也具有显著性差异(p<0.05)。试验中完成全部24个月治疗的患者"}, {"probability": {"variance": 0.089316, "average": 0.692417, "min": 0.39356}, "location": {"width": 52, "top": 169, "height": 30, "left": 1183}, "words": "监"}, {"probability": {"variance": 0.014351, "average": 0.968009, "min": 0.448966}, "location": {"width": 388, "top": 218, "height": 28, "left": 205}, "words": "中,无进展率分别为70%、61%和78‰"}, {"probability": {"variance": 0.087326, "average": 0.702814, "min": 0.407304}, "location": {"width": 52, "top": 210, "height": 31, "left": 1179}, "words": "明"}, {"probability": {"variance": 9e-06, "average": 0.998413, "min": 0.983819}, "location": {"width": 808, "top": 259, "height": 40, "left": 247}, "words": "一项在420位活动性RA患者中进行的双盲、安慰剂对照的临床研究中评价50mg"}, {"probability": {"variance": 0, "average": 0.94855, "min": 0.94855}, "location": {"width": 33, "top": 254, "height": 31, "left": 1199}, "words": "缝"}, {"probability": {"variance": 0.012532, "average": 0.969048, "min": 0.481936}, "location": {"width": 854, "top": 308, "height": 42, "left": 202}, "words": "依那西普(25mg×2,皮下注射)每周一次给药的安全性和有效性。在此项研究中,给"}, {"probability": {"variance": 0.00645, "average": 0.984611, "min": 0.47766}, "location": {"width": 854, "top": 357, "height": 43, "left": 203}, "words": "予53名受试者安慰剂、给予214名受试者50mg依那西音每周1次以及给予153名受"}, {"probability": {"variance": 7.4e-05, "average": 0.996596, "min": 0.960673}, "location": {"width": 857, "top": 407, "height": 43, "left": 200}, "words": "试者25mg依那西普每周2次。在第8周,两种依那西普治疗方案对改善RA指征和症"}, {"probability": {"variance": 0.002446, "average": 0.990662, "min": 0.686511}, "location": {"width": 853, "top": 456, "height": 41, "left": 199}, "words": "状的安全性和有效性相当;第16周的数据并未显示两种治疗方案具有可比性(非劣效)"}, {"probability": {"variance": 5e-06, "average": 0.998176, "min": 0.993887}, "location": {"width": 183, "top": 564, "height": 30, "left": 200}, "words": "成人强直性脊柱炎"}, {"probability": {"variance": 6e-06, "average": 0.99879, "min": 0.98643}, "location": {"width": 816, "top": 604, "height": 40, "left": 243}, "words": "在3项随机、双盲的研究中评价了依那西普治疗强直性脊柱炎的疗效,给药方案为"}, {"probability": {"variance": 1e-05, "average": 0.9981, "min": 0.984614}, "location": {"width": 861, "top": 653, "height": 42, "left": 197}, "words": "每周2次给予25mg依那西普或安慰剂,试验总共入组401例患者,其中203例给予依"}, {"probability": {"variance": 0.000279, "average": 0.995967, "min": 0.892198}, "location": {"width": 850, "top": 703, "height": 39, "left": 197}, "words": "那西普治疗。这三个试验中最大的一个入组的患者年龄在18岁到70岁之间(n=277)"}, {"probability": {"variance": 0.003332, "average": 0.989547, "min": 0.643282}, "location": {"width": 863, "top": 751, "height": 41, "left": 197}, "words": "患有活动性的强直性脊柱炎,其定义为:平均晨僵持续时间和严重程度视觉模拟评分"}, {"probability": {"variance": 0.001087, "average": 0.988645, "min": 0.815886}, "location": {"width": 854, "top": 800, "height": 41, "left": 208}, "words": "(VAS)须≥30分,且有如下3项其它指标中的2项的VAS评分须≥30分:患者总体"}, {"probability": {"variance": 0.000104, "average": 0.995202, "min": 0.942885}, "location": {"width": 852, "top": 849, "height": 41, "left": 196}, "words": "评价、夜间疼痛和背部总疼痛的VAS均值以及Bath强直性脊柱炎功能指数( BASFI)"}, {"probability": {"variance": 0.000423, "average": 0.992068, "min": 0.905059}, "location": {"width": 862, "top": 898, "height": 41, "left": 197}, "words": "平均评分。使用 DMARDS、 NSAIDS或皮质类固醇治疗的患者可在研究期间继续使用这"}, {"probability": {"variance": 8e-06, "average": 0.998559, "min": 0.983569}, "location": {"width": 865, "top": 946, "height": 41, "left": 196}, "words": "些药物的稳定剂量。试验排除脊椎完全强直的患者。138例患者持续6个月每周两次皮"}, {"probability": {"variance": 6e-06, "average": 0.998008, "min": 0.988997}, "location": {"width": 863, "top": 995, "height": 41, "left": 200}, "words": "下注射25mg依那西普或安慰剂治疗(剂量设定是依据在RA患者中进行的剂量摸索试"}, {"probability": {"variance": 0.103675, "average": 0.677709, "min": 0.355723}, "location": {"width": 92, "top": 1026, "height": 35, "left": 766}, "words": "药"}, {"probability": {"variance": 3e-06, "average": 0.997034, "min": 0.994296}, "location": {"width": 108, "top": 1055, "height": 26, "left": 196}, "words": "验确定的)"}, {"probability": {"variance": 0.00015, "average": 0.995931, "min": 0.926997}, "location": {"width": 823, "top": 1091, "height": 40, "left": 240}, "words": "主要有效性指标是强直性脊柱炎评估指标(ASAS20)4项中至少有3项(包括患"}, {"probability": {"variance": 0.00016, "average": 0.995073, "min": 0.923579}, "location": {"width": 856, "top": 1140, "height": 40, "left": 195}, "words": "者的总体评价、背痛、 BASFI和炎症)的改善≥20%(ASAS20),且无其他指标的恶化"}, {"probability": {"variance": 3.3e-05, "average": 0.997432, "min": 0.974355}, "location": {"width": 761, "top": 1189, "height": 42, "left": 194}, "words": "ASAS50和70反应者适用相同的标准,即分别有50%的改善或70%的改善"}, {"probability": {"variance": 0.002105, "average": 0.985877, "min": 0.716289}, "location": {"width": 823, "top": 1238, "height": 38, "left": 240}, "words": "与安慰剂相比,在开始治疗后两周,依那西普治疗患者的ASAS20、ASAS50和ASAS"}, {"probability": {"variance": 7e-06, "average": 0.99879, "min": 0.991928}, "location": {"width": 169, "top": 1297, "height": 28, "left": 194}, "words": "70得到显著改善"}, {"probability": {"variance": 6e-06, "average": 0.998003, "min": 0.991}, "location": {"width": 442, "top": 1337, "height": 36, "left": 408}, "words": "安慰剂对照试验中强直性脊柱炎患者的反应"}, {"probability": {"variance": 3e-06, "average": 0.99799, "min": 0.995758}, "location": {"width": 86, "top": 1395, "height": 26, "left": 724}, "words": "患者比例"}, {"probability": {"variance": 0, "average": 0.999738, "min": 0.999387}, "location": {"width": 68, "top": 1433, "height": 26, "left": 578}, "words": "安慰剂"}, {"probability": {"variance": 1.9e-05, "average": 0.995499, "min": 0.987902}, "location": {"width": 89, "top": 1429, "height": 27, "left": 870}, "words": "依那西普"}, {"probability": {"variance": 3e-06, "average": 0.998249, "min": 0.995081}, "location": {"width": 236, "top": 1452, "height": 28, "left": 204}, "words": "强直性脊柱炎患者的反应"}, {"probability": {"variance": 0.003992, "average": 0.960336, "min": 0.835021}, "location": {"width": 66, "top": 1470, "height": 20, "left": 576}, "words": "N=139"}, {"probability": {"variance": 9e-06, "average": 0.995763, "min": 0.991352}, "location": {"width": 75, "top": 1466, "height": 21, "left": 881}, "words": "N=138"}, {"probability": {"variance": 0.001072, "average": 0.977908, "min": 0.920489}, "location": {"width": 125, "top": 1506, "height": 24, "left": 195}, "words": "ASAS20反应"}, {"probability": {"variance": 0, "average": 0.999516, "min": 0.999232}, "location": {"width": 41, "top": 1542, "height": 21, "left": 210}, "words": "2周"}, {"probability": {"variance": 0, "average": 0.999826, "min": 0.999761}, "location": {"width": 62, "top": 1572, "height": 25, "left": 211}, "words": "3个月"}, {"probability": {"variance": 0, "average": 0.999089, "min": 0.998849}, "location": {"width": 20, "top": 1570, "height": 22, "left": 601}, "words": "27"}, {"probability": {"variance": 0.000106, "average": 0.990201, "min": 0.967142}, "location": {"width": 161, "top": 1640, "height": 25, "left": 192}, "words": "版本号:20090118"}, {"probability": {"variance": 1e-06, "average": 0.998844, "min": 0.996288}, "location": {"width": 178, "top": 1630, "height": 28, "left": 802}, "words": "第19页共31页"}], "language": 3}